CTIS2023-507377-17-00进行中（未招募）1 期
MB097-01
Microbiotica Limited0 个研究点目标入组 40 人开始时间: 2024年3月28日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A Study of NB003 in Patients With Advanced MalignanciesCTIS2022-502401-15-00ingbo Newbay Technology Development Co. Ltd.290
进行中（未招募）
1 期
A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple MyelomaMultiple myelomaCTIS2023-503468-17-00Janssen - Cilag International290
招募中
1 期
Trial to evaluate the administration of IDOR-1134-2831 vaccine in healthy participantsClostridioides difficile (C. difficile)MedDRA version: 20.0Level: PTClassification code: 10054236Term: Clostridium difficile infection Class: 100000004862CTIS2023-506407-26-00Idorsia Pharmaceuticals Ltd.125
招募中
1 期
An exploratory study to investigate the effect of FE 999302 when given during different time periods to women undergoing controlled ovarian stimulation with follitropin deltaInfertility in women undergoing assisted reproductive technologies (ART)CTIS2023-508149-42-00Ferring Pharmaceuticals A/S200
进行中（未招募）
1 期
A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myelomamultiple myelomaCTIS2023-503620-60-00Janssen - Cilag International182